Massive Atropine Eye Drop Ingestion Treated with High-Dose Physostigmine to Avoid Intubation by Stellpflug, Samuel J et al.
CASE REPORT
Massive Atropine Eye Drop Ingestion Treated with High-Dose
Physostigmine to Avoid Intubation
Samuel J. Stellpflug, MD*
†
Jon B. Cole, MD*
†
Brian A. Isaacson, MD
‡
Christian P. Lintner, DBAT
†
Elisabeth F. Bilden, MD
†
* Regions Hospital, Department of Emergency Medicine, Toxicology Education and
Clinical Service, St Paul, Minnesota
† Hennepin Regional Poison Center, Minneapolis, Minnesota
‡ Fairview Ridges Medical Center, Department of Emergency Medicine, Burnsville,
Minnesota
Supervising Section Editor: Rick A McPheeters, DO
Submission history: Submitted May 31, 2011; Revision received July 4, 2011; Accepted July 7, 2011
Reprints available through open access at http://escholarship.org/uc/uciem_westjem
DOI: 10.5811/westjem.2011.7.6817
Case: A 34-year-old male presented after ingesting 150 mg of atropine. He had altered mental status,
sinus tachycardia, dry mucosa, flushed skin, and hyperthermia. Sequential doses of physostigmine,
totaling 14 mg, were successful in reversing antimuscarinic toxicity and prevented the need to perform
airway control with endotracheal intubation. At completion of treatment, heart rate and mental status
had improved, and intubation was never performed.
Discussion: Atropine causes anticholinergic toxicity; physostigmine reverses this by inhibiting
acetylcholinesterase. Atropine eye drop ingestions are rare. The 14 mg of physostigmine administered
is much higher than typical dosing. It is likely the physostigmine prevented intubation. Atropine eye
drops can be dangerous, and physostigmine should be considered in treatment. [West J Emerg Med.
2012;13(1):77–79.]
INTRODUCTION
Atropine, or hyoscyamine, is an alkaloid used commonly
for its antimuscarinic properties.
1 It acts as a competitive
antagonist of acetylcholine at muscarinic receptors. It can be
administered by various routes, including the eye drop
formulation of atropine sulfate, used to induce cycloplegia and
mydriasis.
2 In overdose, atropine can cause tachycardia,
agitation, delirium, dilated pupils, dry mucous membranes, dry
skin, and hypoactive bowel sounds. These phenomena have
been described even with attempted therapeutic ophthalmic
use.
1,3 Ingestion of as little as a few drops of atropine in eye
drop formulation can cause anticholinergic, or more
speciﬁcally antimuscarinic, toxicity.
4 The antimuscarinic
toxidrome results from blockade of the neurotransmitter
acetylcholine at central and peripheral muscarinic receptors.
5
Physostigmine is a carbamate that acts by reversibly
inhibiting acetylcholinesterase. Unlike quaternary amine
acetylcholinesterase inhibitors (such as neostigmine) that treat
peripheral manifestations of the antimuscarinic toxidrome,
physostigmine is a tertiary amine, and thus is able to cross the
blood-brain barrier to treat both central (eg, agitation and
delirium) and peripheral (eg, tachycardia) antimuscarinic
manifestations.
5 The use of physostigmine began as early as the
19th century for its ability to reverse the signs and symptoms of
anticholinergic poisonings. Itspopularity grew in the 1960sand
1970s as a general antidote and diagnostic tool for altered
mental status.
6 A case series published in 1980 illustrated 2
cases of patients who developed asystolic cardiac arrests in the
context of tricyclic antidepressant overdose where treatment
included physostigmine.
7 The frequency of use of this antidote
declined after that report. However, recent literature has
tempered some of the concern about the deleterious effects of
physostigmine, and its use has again become more frequent.
6,8
The usual dose of physostigmine is 0.5 to 2 mg administered by
slow intravenous (IV) push, with repeat doses administered
every 15 to 40 minutes as necessary.
9 It is unusual for doses in
the emergency department to exceed 2 to 4 mg.
We describe an adult male with a massive ingestion of
atropine eye drops treated successfully with 11 mg IV
physostigmine in the emergency department. Successful
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mental status and avoidance of need for intubation.
CASE REPORT
A 34-year-old male presented to an urgent care center,
where he collapsed on arrival in the triage area, per providers in
that department. He stated that he had emptied a full bottle of
atropine eye drop solution into a glass of water and ingested it
in an attempt to harm himself. The atropine concentration was
10 mg/mL, making for a total ingestion of 150 mg. On initial
presentation, he had altered mental status with waxing and
waning coherence, and when awake, he was very combative.
He was also tachycardic with a heart rate (HR) of 125 beats per
minute. A ﬁngerstick glucose was normal. He was given 2 mg
IV lorazepam, 4 mg IVondansetron, 50 gm oral activated
charcoal, and quickly transferred to a larger local hospital for
further care.
In the emergency department at the accepting facility, the
patient continued to have altered mental status, varying
between severe sedation and uncontrolled agitation. His HR
was 150 beats per minute, blood pressure (BP) 150/90 mmHg,
respiratory rate 24 breaths per minute, and oxygen saturation
95% on room air. He had ﬂushed skin, dry oral mucosa,
nonreactive mydriasis, and a rectal temperature of 100.28F. He
showed no signs of trauma and had a nonfocal neurologic
examination other than the gross altered mental status. The
remainder of his physical exam was unremarkable.
Electrocardiogram revealedsinus tachycardia and no interval or
segment abnormalities.
Due to the intermittent somnolence and uncontrolled
agitation, the emergency physicians at the accepting facility
were concerned for the patient’s ability to protect his airway
enough to maintain oxygenation and ventilation. This, in
combination with the recently administered charcoal and the
possibility of emesis with subsequent aspiration, was enough
cause for them to move towards rapid sequence induction (RSI)
and endotracheal intubation. While preparing for the
intubation, a medical toxicologist was consulted by the treating
physicians. In an attempt to avoid the morbidity of the RSI,
intubation, sedation, and mechanical ventilation, the decision
was made to administer physostigmine to reverse the
anticholinergic effects of the atropine.
Over the subsequent 75 minutes, physostigmine was
titrated in 1 mg increments, each given over 3 to 5 minutes to a
total dose of 11 mg. There was minimal change with the initial
few doses, but after the ﬁfth dose had been administered each 1
mg dose improved the patient’s mental status along with
normalizing the heart rate from the tachycardia listed above.
Each of these signs would slowly worsen again over the
ensuing 5 to 15 minutes, necessitating another dose. At the
completion of treatment in the emergency department, the
patient’s HR had declined into the 90s beats per minute, and BP
to 125/80 mmHg. His mental status was normalizing to the
point where he was relatively calm and could provide a little bit
of subjective history.
Laboratory evaluation at the second hospital included a
negative serum ethanol, negative acetaminophen, normal basic
metabolic panel, normal complete blood count, and negative
urine drugs of abuse immunoassay for amphetamines,
barbiturates, benzodiazepines, cannabinoids, cocaine, opiates,
and phencyclidine. A serum atropine level later returned at 240
ng/mL (this was performed using the initial blood draw at the
accepting facility).
Hewas admitted to the intensive care unit (ICU) for further
observation and treatment. During the night in the ICU, he
required 3 additional 1 mg doses of physostigmine for agitation
that recurred. Endotracheal intubation was never performed.
The remainder of the medical portion of his hospital stay was
uneventful.
DISCUSSION
Atropine ingestions are common. In 2008, poison centers
received 1,040 calls regarding plants containing anticholinergic
toxins and 435 calls regarding atropine or diphenoxylate
containing antidiarrheal medications.
10 Ophthalmic preparation
exposures are also a common poison center call with 3,481
calls occurring in 2008.
10 Despite this, a paucity of atropine eye
drop ingestion cases exist in the literature.
Atropine toxicity and lethality are not predictable by dose.
Fatalities have been reported with exposures of less than 100
mg, and survival has been described with doses greater than 1 g
orally.
1 The amount of atropine ingested by the patient in the
case presented above falls into this potentially lethal range. To
put the serum level of 240 ng/mL into perspective, an adult
patient with a reported 1-g ingestion of atropine had a serum
level of 129 ng/mL.
11 A study of 248 cases of accidental
injections with personal autoinjectors demonstrated levels of
7.5 to 69 ng/mL.
12
Making this case more remarkable was the liberal use of
physostigmine. Standard dosing of physostigmine is 0.5 to 2
mg (0.02 mg/kg in children) given intravenously over at least 5
minutes with repeat dosing as needed 15 to 40 minutes later.
9
When repeat dosing is needed, 4 mg total is usually sufﬁcient.
9
Our case is also unique in that physostigmine was administered
in more rapid succession, and a total dose of 14 mg was
required to control agitation and reverse delirium. The large
amount of physostigmine required to treat this patient was
likely due to the massive amount of atropine ingested,
conﬁrmed by the serum level of 240 ng/mL.
This case illustrates one of the most beneﬁcial aspects of
physostigmine use: the ability to control agitation and reverse
delirium, thereby reducing the need for invasive interventions.
Physostigmine administration, in this case, prevented the need
for intubation, thus preventing patient exposure to the potential
complications of this invasive procedure. This may be
understated at ﬁrst glance, but the morbidity of RSI, intubation,
and mechanical ventilation are serious and well established.
13,14
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the need for intubation and potentially lowering the level of
observation needed for a patient in the hospital, there are some
concerns about the safety of the antidote itself. As mentioned
earlier, much of this concern is likely unfounded and is based
on a case series with questionable causality between the
physostigmine and the negative outcomes.
7 The most recent
look in the literature on this topic is a retrospective case series
including hundreds of patients that received the antidote. There
was a seizure rate of less than 1% (all were self-limited) and
there were no cardiac arrhythmias.
15 The above beneﬁts and
risks of both physostigmine and intubation need to be weighed
when deciding whether or not to use this treatment in this
clinical scenario.
CONCLUSION
An oral overdose of atropine sulfate eye drops with severe
altered mental status reversed with physostigmine is unique to
the literature. Additionally, the dose of physostigmine
administered was much higher than what is usually
recommended or necessary. It is highly likely that the
physostigmine administration prevented the potential
morbidity of intubation and mechanical ventilation for the
patient. Eye drops should be considered a potentially dangerous
means of atropine exposure, and physostigmine should be
considered in cases similar to this one with the goal of
improving patient care and use of hospital resources. While the
authors are not advocating a blanket use of high dose
physostigmine for known antimuscarinic overdoses such as the
one in this case, this treatment method may be considered if the
likely beneﬁt appears to outweigh a potential morbidity-
inducing alternative.
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